Community Bank & Trust Waco Texas decreased its stake in shares of Novartis AG (NYSE:NVS) by 4.2% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 4,559 shares of the company’s stock after selling 200 shares during the period. Community Bank & Trust Waco Texas’ holdings in Novartis AG were worth $376,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new position in shares of Novartis AG during the first quarter valued at about $1,234,000. Pacad Investment Ltd. bought a new stake in Novartis AG during the first quarter valued at $261,000. AR Asset Management Inc. raised its stake in Novartis AG by 138.6% in the first quarter. AR Asset Management Inc. now owns 17,300 shares of the company’s stock valued at $1,253,000 after buying an additional 10,050 shares in the last quarter. Ngam Advisors L.P. raised its stake in Novartis AG by 34.9% in the first quarter. Ngam Advisors L.P. now owns 776,559 shares of the company’s stock valued at $56,255,000 after buying an additional 200,917 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its stake in Novartis AG by 79.3% in the first quarter. Stratos Wealth Partners LTD. now owns 24,728 shares of the company’s stock valued at $1,791,000 after buying an additional 10,939 shares in the last quarter. Institutional investors own 9.78% of the company’s stock.
Novartis AG (NYSE:NVS) traded up 0.05% during mid-day trading on Monday, reaching $79.00. The company had a trading volume of 1,162,587 shares. The firm’s 50-day moving average price is $80.27 and its 200-day moving average price is $78.82. Novartis AG has a 12 month low of $69.90 and a 12 month high of $95.11. The stock has a market cap of $188.12 billion, a PE ratio of 28.20 and a beta of 0.57.
Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 19th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.18 by $0.05. The company earned $12.47 billion during the quarter, compared to analysts’ expectations of $12.33 billion. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. During the same quarter in the previous year, the company posted $1.25 EPS. Equities research analysts forecast that Novartis AG will post $4.72 EPS for the current fiscal year.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Novartis AG from a “sell” rating to a “hold” rating in a research note on Wednesday, June 15th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis AG in a research note on Tuesday, July 19th. TheStreet lowered Novartis AG from a “buy” rating to a “hold” rating in a research note on Wednesday, September 28th. Chardan Capital assumed coverage on Novartis AG in a research note on Tuesday, September 20th. They set a “buy” rating and a $95.00 price objective for the company. Finally, Bank of America Corp. reissued a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 12th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $91.83.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.